Key facts
- Loyal’s last known valuation is $430.0M (Feb 2025).
- It has raised $236.5M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($27.7M) in Sep 2021.
- Notable investors include Khosla Ventures, Gaingels, Metaplanet Holdings, BoxGroup, Pareto Holdings — 42 tracked in total.
- 1 investment vehicle was formed to buy Loyal shares in the last 12 months, reporting $638K sold to 40 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 42 names
- ·Watchlist + deal alerts for Loyal
Funding rounds
1 roundsSecondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Loyal shares, reporting $638K sold to 40 investors. Most recent filing Jan 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Loyal
Developer of veterinary drugs designed to improve dogs' health span and lifespan. The company's drugs delay the onset of age-related diseases like cancer, heart disease, and metabolic diseases, enabling pet owners to help their dogs live healthier and longer lives.
- Industry
- Other Pharmaceuticals and Biotechnology
- Sector
- Consumer Products and Services (B2C)
- HQ
- San Francisco, CA, United States
- Founded
- 2019
- Employees
- 195
- Website
- loyal.com/
- Ownership
- Privately Held (backing)
Loyal doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Loyal shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Loyal in its N-PORT filings yet. We sweep new filings monthly.